Decrease in accelerometer assessed physical activity during the first-year post-myocardial infarction: a prospective cohort study by Amanda Lönn (11583010)

S2 Data - by Dwight D. Harris (14484648)

“…Immunoblot showed a reduction in Jak2, the pSTAT3 to STAT 3 Ratio, pSMAD 2/3, and SMAD 2/3, and an increase in STAT 3 in the SIT group relative to CON (all p<0.05). …”

Human adenovirus (HAdV) types HAdV-5 and HAdV-37 show decreased transduction efficiencies after treatment with cold atmospheric plasma (CAP). by Oskar Bunz (5900291)

Cells with impaired Ssa2p•Mas5 complex have decreased cortical Cdc42 activity and exhibit monopolar intermittent growth pattern. by Aleksandar Vjestica (262087)

A prepubertal CD decreases plasma leptin and cholesterol concentrations in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial by ALINE TABORDA FLESCH (12724983)

Methods of assessment of the glottic gap using a rigid endoscope. by Ikuo Mikoshiba (9312007)

Subjects:

Supplementary Material for: Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala by Butler-Dawson J. (8569992)

Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients by Anni A. Winckelmann (407551)

“…We observed a mean reduction in proviral DNA in the CPG group of 12.6% (95% CI: −23.6–0.0) following each immunization whereas proviral DNA in the placebo-adjuvant group remained largely unchanged (6.7% increase; 95% CI: −4.2–19.0 after each immunization, p = 0.02). …”

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

Subjects:

A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

“…<b>(C)</b> The mutant CLCuMuV carrying C4^R13A (CLCuMuV-C4^R13A), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

“…<b><i>Introduction:</i></b> Prevention of attacks is a major goal in management of patients with hereditary angioedema (HAE). We aimed to investigate the effects of a systematic intervention for HAE patients. …”

Fig 5 - by Hannah N. Marmor (14046394)

Number of species that we predict will not change U.S. Shorebird Conservation Plan Risk Categories due to climate change (0), and the number that will have increased risk of extinc... by Hector Galbraith (636637)

Responding Vγ9Vδ2-individuals decreases among HIV-infected patients who present lower Vγ9Vδ2 T-cell number than HD. by Rita Casetti (608635)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”